(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Matchpoint Therapeutics partners with Novartis to develop oral covalent inhibitors for inflammatory diseases, with potential ...

Swiss pharma major Novartis (NOVN: VX) has entered into an exclusive option and license deal with Matchpoint Therapeutics to ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

Matchpoint Therapeutics Inc. and Novartis AG have entered into an exclusive option and license agreement to develop and commercialize oral covalent inhibitors targeting a transcription factor linked ...

Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

SAN DIEGO--(BUSINESS WIRE)--Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop ...